Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

THREE-QUARTERS OF DERMATOLOGISTS WANT SUNBEDS BANNED AMID SKIN CANCER RISE, POLL REVEALS

The majority of British dermatologists believe that sunbeds should be banned in the UK, a new survey has found.

READ MORE >

Posted in Melanoma News, Patients, Latest News

Smoking, Vitamin D Deficiency Correlate to Ulcerated Melanoma

Ulcerated melanoma is associated with worse outcomes and appears to be driven in part by systemic inflammation, which is more common in smokers, obese individuals, and those with vitamin D deficiency, according to melanoma expert Julia Newton-Bishop, MD, part of a team of investigators exploring genetic and environmental predictors of the immune response in patients […]

READ MORE >

Posted in Melanoma News, Health Professionals, Video Reports

Tumor-Infiltrating Lymphocytes ‘Capable of Destroying the Last Cancer Cell’

Nearly a quarter of patients, 23.7%, treated with adoptive cell transfer tumor-infiltrating lymphocytes for metastatic melanoma have experienced complete and durable responses, according to data presented at ASCO Annual Meeting.

READ MORE >

Posted in Melanoma News, Health Professionals, Of Interest

Pembrolizumab vs ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Researchers describe findings after a 5-year follow-up among participants of an open-label, multicenter, randomized, controlled, phase 3 study assessing pembrolizumab vs ipilimumab in patients with advanced melanoma.

READ MORE >

Posted in Melanoma News, Publications, Scientific Publications